Importantly, a genetically guided approach is emerging: stratifying patients according to TOLLIP or TLR polymorphisms may assist in identifying those most likely to benefit from specific immune modulators, reducing the risk of broad immunosuppression and its associated infections. The gene discussed is TOLLIP; the disease is infection.